CD1D and glioma: Furthermore, the expanded NKT cells demonstrated significant cytotoxic activity ex vivo against U251 glioma cells, a CD1d expressing cell line, in a Cr51 release assay compared to A172 glioma cells, a CD1d negative cell line [161].